含克力芝HAART方案引起高脂血症临床干预的研究

The research of medical intervention on hyperlipemia caused by anti-virus regimens containing Aluvia

目的比较阿托伐他汀与血脂康胶囊对含克力芝抗病毒治疗方案引起的高脂血症的疗效,探讨此类高脂血症的治疗方法。方法将60例使用含克力芝抗病毒治疗方案引起高脂血症的患者,随机分为观察组和对照组,每组各30例。观察组给予阿托伐他汀治疗,对照组给予血脂康胶囊治疗。治疗24周后比较两组的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)的水平。结果观察组降血脂的总有效率为93.3%(28/30),高于对照组的46.7%(14/30),差异有统计学意义(P<0.05)。24周疗程结束后,2组血清TC、TG、LDL-C水平均低于治疗前,HDL-C高于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。结论与血脂康胶囊相比,在抗病毒治疗中使用阿托伐他汀可更为有效地控制由克力芝抗病毒治疗方案引起的高脂血症,值得临床推广使用。

Objective To compare the efficacy of atorvastatin and Xueztfikang capsule on hyperlipemia induced by Aluvia-based antiretroviral therapy and to explore treatment of such hyperlipemia. Methods A total of 60 patients with hyperlipemia incuded by Aluvia-based antiretroviral therapy were randomly and equally assigned into control group and observation group. Patients in the observation group were treated with atorvastatin, while those in control group received Xuezhikang capsule. After 24 weeks of intervention, changes of total cholesterol （TC）, triglyceride （TG）, high density lipoprotein （HDL-C） and low density lipoprotein（LDL-C） were measured. Results The overall response rate of the observation group was 93.3% （28/30）, which was significantly higher than that of control group （46.7%, 14/30） （P〈0. 05）. After 24 weeks of intervention, TC, TG, and LDL-C were decreased compared with the baseline values in both the two groups, while HDL-C was increased. The effect of the observation group was significantly superior to that of the control group （P〈0.05）. Conclusion Compared with Xuezhikang Capsule, atorvastatin is more effective on controlling hyperlipemia induced by Aluvia-based antiretroviral therapy, which should be promoted in the clinical practice.